Questcor Sees No Adverse Effect From Aetna Payment Change
This article is for subscribers only.
Questcor Pharmaceuticals Inc., which sank the most in 20 years yesterday after insurer Aetna Inc. said it would limit coverage of the company’s top-selling drug, is in discussions with the insurer and doesn’t expect the decision to hurt business, executives told investors.
“We do not expect the bulletin to have a material adverse impact,” Chief Executive Officer Don Bailey said today on a conference call. Reimbursement decisions are made on a case-by-case basis, he said.